Advertisement
Canada markets open in 2 hours 16 minutes
  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     
  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     
  • DOW

    38,852.86
    -216.74 (-0.55%)
     
  • CAD/USD

    0.7314
    -0.0023 (-0.31%)
     
  • CRUDE OIL

    80.44
    +0.61 (+0.76%)
     
  • Bitcoin CAD

    92,666.62
    -1,032.28 (-1.10%)
     
  • CMC Crypto 200

    1,464.49
    -20.21 (-1.36%)
     
  • GOLD FUTURES

    2,346.60
    -9.90 (-0.42%)
     
  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     
  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     
  • NASDAQ futures

    18,815.50
    -125.00 (-0.66%)
     
  • VOLATILITY

    14.08
    +1.16 (+8.97%)
     
  • FTSE

    8,232.36
    -21.82 (-0.26%)
     
  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     
  • CAD/EUR

    0.6745
    -0.0007 (-0.10%)
     

InspireMD Insider Ups Holding By 13% During Year

Insiders were net buyers of InspireMD, Inc.'s (NASDAQ:NSPR ) stock during the past year. That is, insiders bought more stock than they sold.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for InspireMD

The Last 12 Months Of Insider Transactions At InspireMD

Over the last year, we can see that the biggest insider purchase was by insider Gary Roubin for US$127k worth of shares, at about US$2.53 per share. That means that even when the share price was higher than US$2.40 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Gary Roubin was the only individual insider to buy during the last year.

ADVERTISEMENT

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of InspireMD

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that InspireMD insiders own 22% of the company, worth about US$12m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About InspireMD Insiders?

It doesn't really mean much that no insider has traded InspireMD shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in InspireMD and their transactions don't cause us concern. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 3 warning signs for InspireMD (2 make us uncomfortable) you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.